Key result
Remotely monitored implantable loop recorder surveillance led to an arrhythmia-driven management change in 42.0% of patients.
Why the study?
Restricted reimbursement limits access to implantable loop recorders in several healthcare systems, including Poland, motivating evaluation of the safety and diagnostic yield of ILR monitoring in a tertiary center without dedicated reimbursement.
Cohort (n=50)
No
In a real-world tertiary setting with restricted reimbursement, remotely monitored implantable loop recorders detected clinically relevant arrhythmias in 70% of patients and prompted management changes in 42%.
Answers are grounded in this paper and cite their sources.
Suggests arrhythmia monitoring may drive management changes; hypothesis-generating and should not yet change practice.
Background/Objectives: Implantable loop recorders (ILRs) provide prolonged, remotely monitored rhythm surveillance, but restricted reimbursement limits access in several healthcare systems, including Poland. We evaluated the safety and diagnostic yield of ILR monitoring in a tertiary center without dedicated reimbursement. Methods: We retrospectively analyzed consecutive patients undergoing ILR implantation (March 2013–November 2023); all devices were remotely monitored. The primary endpoint was an arrhythmia-driven management change (a management change resulting from an ILR-documented arrhythmia), analyzed per patient and per implantation episode. Results: Fifty patients (median age 58.1 years; 52.0% female) underwent 51 implantations, mostly for unexplained syncope (82.4%). The median symptom-to-implantation interval was 36 (interquartile range [IQR] 9–102) months. Over a median of 1290 (IQR 507–1519) monitoring days, clinically relevant arrhythmias were detected in 35 patients (70.0%). An arrhythmia-driven management change occurred in 21 patients (42.0%, 95% confidence interval 29.4–55.8%; Kaplan–Meier estimate 26.1% at 12 months), and every underlying arrhythmia was first identified by remote monitoring. These changes comprised cardiac implantable electronic device implantation in 13 patients (26.0%), catheter ablation in 4 (8.0%) and pharmacotherapy modification in 8 (16.0%). There were no acute procedural complications; pocket infection required explantation of 2 devices, and one non-cardiac death occurred. Conclusions: In this selected cohort under restricted reimbursement, remotely monitored ILR surveillance had an acceptable safety profile and led to an arrhythmia-driven management change in more than two in five patients. These single-arm data cannot quantify the effects of reimbursement policy or remote monitoring but support prospective comparative and economic evaluation of broader ILR access.
No takes yet. Share an insight, caveat, or question.
Rokicki et al. (2026) conducted a cohort in Unexplained syncope and arrhythmia monitoring indications (n=50). Implantable loop recorder (ILR) monitoring with remote surveillance was evaluated on Arrhythmia-driven management change (a management change resulting from an ILR-documented arrhythmia) (95% CI 29.4-55.8). Remotely monitored implantable loop recorder surveillance led to an arrhythmia-driven management change in 42.0% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: